KPG-121 in Castration Resistant Prostate Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

KPG-121 in Castration Resistant Prostate Cancer

Sponsor: Kangpu Biopharmaceuticals, Ltd.

KPG-121-101: A study using KPG-121 plus enzalutamide for patients with metastatic castration resistant prostate cancer whose PSA has failed, after 3 months, to respond to treatment with enzalutamide alone.